NSE · MEDICAPQ · Realty
Medi-Caps Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹0 Cr with net profit ₹-1 Cr — a -441.67% net margin, versus -590% the period before.
Shareholding
As of 2026-09-30
- Promoter51.44%
- Public48.54%
- DII0.02%
10,369 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.81× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Construction · ranked #253 of 382 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| DLF Limited | ₹1,87,814 Cr | 40.86 | 4.1 | 10.02% | 71.64% |
| Lodha Developers Limited | ₹1,21,939 Cr | 28.03 | 4.92 | 17.2% | 23.08% |
| The Phoenix Mills Ltd. | ₹80,660 Cr | 60.95 | 8.76 | 14.31% | 28.41% |
| Prestige Estates Projects Ltd. | ₹71,070 Cr | 76.21 | 4.26 | 5.6% | 7.35% |
| Oberoi Realty Limited | ₹65,361 Cr | 24.68 | 3.42 | 13.78% | 42.34% |
| Godrej Properties Ltd. | ₹55,875 Cr | 40.87 | 2.88 | 6.97% | 21.09% |
| Knowledge Realty Trust | ₹49,266 Cr | 45.91 | 1.16 | 2.52% | 21.93% |
| Rail Vikas Nigam Limited | ₹41,588 Cr | 46.28 | 4.12 | 9.1% | 4.5% |
| Embassy Office Parks REIT | ₹40,674 Cr | 48.16 | — | 4.1% | 19.78% |
| Bagmane Prime Office REIT | ₹36,118 Cr | 41.59 | 1.02 | 0% | 38.89% |
| Medi-Caps Ltd.(this company) | ₹29 Cr | 11.25 | 0.24 | -4.04% | -0.31% |
AI analysis
AI-generated · google/gemini-2.5-flashMedi-Caps Ltd., operating in the Realty sector, has a market capitalization of Rs 32 Cr. The company's PE ratio stands at 10.76 and its book value is Rs 89.5. It reported a negative profit margin of -24.52%. The share price has ranged between Rs 21 and Rs 46.99 over the last 52 weeks.
Positives
- +The company has a low debt-to-equity ratio of 0.
- +Promoter holding is above 50% at 51.4425% as of June 30, 2026.
- +There are no pledged promoter shares, with promoter pledge at 0%.
Negatives
- −The company reported negative return on equity (ROE) of -272.15%.
- −Return on capital employed (ROCE) is negative at -2.6972%.
- −The profit margin is negative at -24.52%.
- −Earnings per share (EPS) for March 2025 was negative at -Rs 0.46.
- −The number of shareholders increased from 4310 in September 2016 to 10209 in June 2026, which may indicate increased retail interest without necessarily reflecting fundamental strength.
Financial Performance
Medi-Caps Ltd. reported a revenue of Rs 3.45 Cr for March 2026, with a net profit of Rs 3.04 Cr. In the December 2025 quarter, revenue was Rs 4.3 Cr, resulting in a net profit of -Rs 0.77 Cr. The company's annual revenue for March 2025 was Rs 28.2066 Cr, with a net profit of -Rs 0.571 Cr. More recent quarterly results show a revenue of Rs 0.53 Cr and a net profit of -Rs 0.31 Cr for March 2026.
Profitability & Returns
The company reported a return on equity (ROE) of -272.15% and a return on capital employed (ROCE) of -2.6972%. The overall profit margin is -24.52%. Earnings per share (EPS) for March 2025 was -Rs 0.46. For the three months ending March 2026, the company reported an EPS of 0. Similarly, EPS was 0 in June 2025, September 2025, and December 2025.
Balance Sheet
Medi-Caps Ltd. has a debt-to-equity ratio of 0, indicating no debt. The book value per share is Rs 89.5. The company's financial position reflects a market capitalization of Rs 32 Cr against these metrics.
Ownership & Pledges
There are no pledged promoter shares, with promoter pledge at 0%.
Data as of — price: 2026-11-14 · financials: Sep 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.